TCL Archive Phase III Trebananib Trial Fails OS Endpoint In Recurrent Platinum-Resistant Ovarian Cancer November 28, 2014
TCL Archive OMB Restrictions On Reprogramming Could Result In Inefficient Last Minute Spending By Institutes September 13, 1985
TCL Archive Professional Societies: Tobacco Industry Should Pay For Research, AACR Says August 15, 1997
TCL Archive FDA Advisory Committee Recommends Approval Of Ifosfamide as Third Line Therapy For Testicular Cancer April 29, 1988
